Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY 355703

Known as: LY-355703, LY355703 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cryptophycin 52

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum‐resistant ovarian cancer
LY355703 is a synthetic product structurally related to the cryptophycin family isolated from the blue-green algae, which exerts… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2004
2004
Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Cryptophycin 52 (LY355703) is a potent antiproliferative analogue of the marine natural product cryptophycin 1. It has been shown… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Highly Cited
2003
Highly Cited
2003
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
BACKGROUND Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based… Expand
2003
2003
Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
A highly enantioselective and convergent synthesis of cryptophycin 52 (2), an exceedingly potent cytotoxic agent, is described… Expand
Highly Cited
2002
Highly Cited
2002
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
LY355703 is a synthetic derivative of the marine cryptophycins, cytotoxic agents which induce mitotic arrest by binding at the… Expand
2002
2002
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
We assessed the ability of cryptophycin 52 (LY355703), a novel antimicrotubule, to induce growth arrest and apoptosis in prostate… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
2002
2002
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
The cryptophycin analogue LY355703 is a potent inhibitor of microtubule polymerization that displays in vitro and in vivo… Expand
  • figure 1
  • table 2
  • table 1
  • table 3
  • figure 2
2000
2000
Interaction of the antitumor compound cryptophycin-52 with tubulin.
Cryptophycin-52 (LY355703) is currently undergoing clinical evaluation for cancer chemotherapy. It is a potent suppressor of… Expand
Highly Cited
1999
Highly Cited
1999
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines
Purpose: Cryptophycin 52 (LY355703) is a new member of the cryptophycin family of antitumor agents that is currently undergoing… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
1998
Highly Cited
1998
Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Cryptophycin-52 (LY355703) is a new synthetic member of the cryptophycin family of antimitotic antitumor agents that is currently… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE